CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates

Core Insights - CorMedix (CRMD) reported quarterly earnings of $0.28 per share, exceeding the Zacks Consensus Estimate of $0.20 per share, and showing a significant improvement from a loss of $0.25 per share a year ago [1] - The company achieved revenues of $39.74 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.94%, compared to revenues of $0.81 million in the same quarter last year [2] - CorMedix has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Performance - The earnings surprise for the recent quarter was +40.00%, following a previous surprise of +20% when actual earnings were $0.30 per share against an expectation of $0.25 [1][2] - The current consensus EPS estimate for the upcoming quarter is $0.22, with expected revenues of $39.89 million, and for the current fiscal year, the EPS estimate is $0.97 on revenues of $159.01 million [7] Stock Performance and Outlook - CorMedix shares have increased approximately 47.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] - The company's favorable estimate revisions trend prior to the earnings release has resulted in a Zacks Rank 1 (Strong Buy), indicating expectations for continued outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which CorMedix belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]